Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$40.97 USD

40.97
18,118,097

-0.23 (-0.56%)

Updated Jun 17, 2024 04:00 PM ET

After-Market: $40.97 0.00 (0.00%) 5:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

by Zacks Equity Research

The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) reachead $43.02 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

by Zacks Equity Research

Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.

Replimune (REPL) Gains on Positive Data From Melanoma Study

by Zacks Equity Research

Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

by Zacks Equity Research

Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo

by Zacks Equity Research

Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $41.77, moving +1.65% from the previous trading session.

Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

by Zacks Equity Research

Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.

Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.

Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday

by Zacks Equity Research

Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.

Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo

by Zacks Equity Research

The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

by Zacks Equity Research

Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.

Sheraz Mian headshot

Walmart Earnings & the State of the Consumer

by Sheraz Mian

We discuss what Walmart's blockbuster results tell us about the health of the consumer economy.

Ekta Bagri headshot

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

by Ekta Bagri

Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

by Zacks Equity Research

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

by Zacks Equity Research

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

Sweta Killa headshot

A Look at Pharma ETFs Post Q1 Earnings

by Sweta Killa

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

by Zacks Equity Research

Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.